Abstract
Three patients with premenstrual dysphoric disorder (PMDD) and recurrent vulvovaginal candidiasis (VVC) underwent sertraline therapy (Tresleen, a selective serotonin-reuptake inhibitor; Pfizer) for PMDD. During sertraline intervention, patients had no recurrent episodes of acute VVC. Antifungal activity was observed for sertraline against various isolates of Candida species.
Cite
CITATION STYLE
Lass-Flörl, C., Dierich, M. P., Fuchs, D., Semenitz, E., & Ledochowski, M. (2001). Antifungal activity against Candida species of the selective serotonin-reuptake inhibitor, sertraline. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 33(12), 135–136. https://doi.org/10.1086/324589
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
